Edwards Lifesciences Corporation
Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS fell 26.3%, free cash flow grew 142.8% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.
Follow EW
Edwards Lifesciences Corporation (EW) Return on assets
Edwards Lifesciences Corporation's return on assets over the twelve months to 30 June 2026 was 7.35%, down 0.7 percentage points from fiscal 2025 (8.03%). Over the past ten years it has ranged from 8.03% (fiscal 2025) to 37.2% (fiscal 2024) — the current reading is the lowest in ten years. That is above the Medical Devices industry median of −19.7% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 8.03% | (29.21) |
| FY2024 | 37.2% | 21.35 |
| FY2023 | 15.9% | (2.23) |
| FY2022 | 18.1% | (0.98) |
| FY2021 | 19.1% | 7.10 |
| FY2020 | 12.0% | (5.73) |
| FY2019 | 17.7% | 4.59 |
| FY2018 | 13.1% | 1.67 |
| FY2017 | 11.5% | (1.83) |
| FY2016 | 13.3% | 0.24 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| DXCM DexCom, Inc. compare | 14.5% |
| BSX Boston Scientific Corporation compare | 8.47% |
| SYK Stryker Corporation compare | 7.91% |
| STE STERIS plc compare | 7.62% |
| EW Edwards Lifesciences Corporation | 7.35% |
| MDT Medtronic PLC compare | 5.68% |
| GEHC GE HealthCare Technologies Inc. compare | 5.45% |
| PHG Koninklijke Philips N.V. compare | 4.21% |
| ZBH Zimmer Biomet Holdings, Inc. compare | 3.53% |
| Medical Devices industry median | −19.7% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on EW
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement